Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines

What happened

Moderna announced on November 5, 2026, that Health Canada authorized its mFLUSIVA seasonal influenza vaccine and mCOFLU combined influenza and COVID-19 vaccine for adults aged 50 and older. Canada is the first country to authorize both products, which Moderna describes as its first mRNA vaccines in these categories there.

Confirmed

Global impact / market context

The authorizations allow Moderna to offer two new vaccine options to eligible adults in Canada, potentially creating a route to sales from seasonal vaccination. Revenue will depend on factors not stated here, including rollout timing, uptake, and how the vaccines are supplied and paid for.

Analyst inference

The article reports a Canadian regulatory milestone, not evidence of sales, pricing, or financial forecasts. It also says the U.S. Food and Drug Administration had approved mFLUSIVA, but gives no details on U.S. timing or the status of mCOFLU there.

Confirmed

What to watch

1. Watch for Moderna or Canadian authorities to announce when each vaccine will be available, since timing determines when eligible adults can begin receiving them. Analyst inference
2. Look for details on Canadian purchasing, payment, and supply arrangements; these would help show whether authorization translates into doses delivered and revenue for Moderna. Analyst inference
3. The article says mFLUSIVA had received U.S. Food and Drug Administration approval, but provides no corresponding U.S. status for the combination vaccine, mCOFLU. Confirmed

Evidence

• accessnewswire.com